Prescription Drugs

Public Opinion on Prescription Drugs and Their Prices

  • by

This charticle draws on recent KFF poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices.

FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries

  • by

The question of what would happen when a new, expensive prescription drug comes to market for a disease like Alzheimer’s that afflicts millions of people has loomed large in discussions over drug prices in the U.S. This brief analyzes the cost implications for Medicare and… Read More »FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries

Utilization and Spending Trends in Medicaid Outpatient Prescription Drugs, 2015-2019

Prescription drug spending in Medicaid and other health programs has returned to the national policy debate. This analysis examines Medicaid outpatient prescription drug utilization and spending before rebates over the 2015 to 2019 period, which is helpful for understanding recent cost drivers and areas for… Read More »Utilization and Spending Trends in Medicaid Outpatient Prescription Drugs, 2015-2019

Two-Thirds of the Public Say the U.S. Should Play a Major Role in Distributing COVID-19 Vaccines Globally, But Not Most Republicans

With increased attention to the global need for COVID-19 vaccines and the Biden administration’s announcement today about how it plans to distribute the first portion of the 80 million doses it will share by the end of this month, the latest KFF Health Tracking Poll… Read More »Two-Thirds of the Public Say the U.S. Should Play a Major Role in Distributing COVID-19 Vaccines Globally, But Not Most Republicans

Biden Administration Signals It’s in No Rush to Allow Canadian Drug Imports

Use Our Content It can be republished for free. The Biden administration said Friday it has no timeline on whether it will allow states to import drugs from Canada, an effort that was approved under President Donald Trump as a key strategy to control costs.  Six states have passed laws to start such programs, and Florida, Colorado and New… Read More »Biden Administration Signals It’s in No Rush to Allow Canadian Drug Imports

A New Analysis Takes a Closer Look at Online Contraception Platforms Amid the Pandemic

Even prior to the COVID-19 pandemic, hormonal contraception became more accessible to many outside of traditional clinical settings through websites or apps that offer contraception via telehealth. To better understand this emerging method of contraceptive access, a new KFF analysis provides a deeper look at… Read More »A New Analysis Takes a Closer Look at Online Contraception Platforms Amid the Pandemic

Analysis Finds That a Relatively Small Number of Drugs Account for the Majority of Medicare Prescription Drug Spending

  • by

A new KFF analysis finds that a relatively small share of drugs, mainly those without generic or biosimilar competitors, accounted for a disproportionate share of prescription drug spending in Medicare in 2019. This finding suggests that recent proposals that focus on prices for a limited… Read More »Analysis Finds That a Relatively Small Number of Drugs Account for the Majority of Medicare Prescription Drug Spending

Relatively Few Drugs Account for a Large Share of Medicare Prescription Drug Spending

  • by

As policymakers focus attention on proposals to lower prescription drug costs by allowing price negotiation or international reference pricing for a limited number of drugs, this analysis measures the share of total Medicare Part D and Part B prescription drug spending accounted for by top-selling… Read More »Relatively Few Drugs Account for a Large Share of Medicare Prescription Drug Spending

A Status Report on Prescription Drug Policies and Proposals at the Start of the Biden Administration

  • by

This brief provides a status update on prescription drug final rules advanced by the Trump Administration in its final months related to Medicare, importation, and 340B pricing for insulin and epinephrine, and an overview of key drug pricing proposals related to Medicare and prescription drug… Read More »A Status Report on Prescription Drug Policies and Proposals at the Start of the Biden Administration

How Can Trump Administration Regulations Be Reversed?

  • by

With the inauguration of President Biden and Democrats holding a slim majority in Congress, policymakers are likely to consider whether and how to reverse various health policy regulations issued by the Trump Administration.

Biden’s First Order of Business May Be to Undo Trump’s Policies, but It Won’t Be Easy

  • by

The party split in Congress is so slim that, even with Democrats technically in the majority, passing major health care legislation will be extremely difficult. So speculation about President-elect Joe Biden’s health agenda has focused on the things he can accomplish using executive authority. Although… Read More »Biden’s First Order of Business May Be to Undo Trump’s Policies, but It Won’t Be Easy

Surprise Federal Drug Rule Directs Insurers to Reveal What They Pay for Prescription Drugs

  • by

Health insurance companies will have to give their customers estimated out-of-pocket costs for prescription drugs and disclose to the public the negotiated prices they pay for drugs, under an unexpected new Trump administration rule. The administration said those requirements, part of a broader rule issued… Read More »Surprise Federal Drug Rule Directs Insurers to Reveal What They Pay for Prescription Drugs

Joe Biden’s Big Lead on Health Care Issues

  • by

In an Axios column, Drew Altman discusses how this election year health isn’t a single issue — but several — and Joe Biden has the edge over President Trump on all of them, even as opposition to the ACA remains popular with Trump’s base.  

2020 Employer Health Benefits Survey

  • by

This annual survey of employers provides a detailed look at trends in employer-sponsored health coverage, including premiums, employee contributions, cost-sharing provisions, offer rates, wellness programs, and employer practices. Annual premiums for employer-sponsored family health coverage reached $21,342 this year, up 4% from last year, with… Read More »2020 Employer Health Benefits Survey